🇺🇸 Locapred@ in United States
79 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 79
Most-reported reactions
- Drug Ineffective — 15 reports (18.99%)
- Cutaneous T-Cell Lymphoma — 12 reports (15.19%)
- Psoriasis — 11 reports (13.92%)
- Pruritus — 7 reports (8.86%)
- Rectal Haemorrhage — 7 reports (8.86%)
- Adenocarcinoma Of Colon — 6 reports (7.59%)
- Dermatitis Exfoliative Generalised — 6 reports (7.59%)
- Off Label Use — 5 reports (6.33%)
- Pyrexia — 5 reports (6.33%)
- Tooth Abscess — 5 reports (6.33%)
Other Dermatology approved in United States
Frequently asked questions
Is Locapred@ approved in United States?
Locapred@ does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Locapred@ in United States?
Pierre Fabre Medicament is the originator. The local marketing authorisation holder may differ — check the official source linked above.